World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases

Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders

Cision PR Newswire by Cision PR Newswire
June 29, 2026
in Press Releases
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

MILWAUKEE, June 29, 2026 /PRNewswire/ — Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zymeworks.


Ademi & Fruchter Logo (PRNewsfoto/Ademi LLP)

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

Theravance Biopharma shareholders will receive $17.00 per share in cash, representing an equity value of approximately $929 million. Theravance Biopharma shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture, or other monetization of ampreloxetine over the next ten years. Zymeworks will retain the remaining 20% of such proceeds.
Theravance Biopharma insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Theravance Biopharma by imposing a significant penalty if Theravance Biopharma accepts a competing bid. We are investigating the conduct of the Theravance Biopharma board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-theravance-biopharma-inc-is-obtaining-a-fair-price-for-public-shareholders-302813144.html

SOURCE Ademi LLP

Cision PR Newswire

Cision PR Newswire

Related Posts

Intercontinental Exchange Launches Data Center Risk Tool: NYSE Content Update

November 17, 2026

Discount Tire Delivers Low Prices and Price Matching Ahead of Black Friday

November 17, 2026

FairMarketValue Introduces Private-Company Financial Benchmarks Built on 1.24 Million Actual Financial Statements

November 17, 2026

Enterprise AI Executive Behind $2B+ in Value Joins Vibrant Capital’s CxO in Residence Program

November 17, 2026

OpFix founder publishes 2 books on why founder-led businesses stall and what money really costs them

November 17, 2026

ElectricBillMath.com Analysis: Maryland Homes Paid $247 a Month for Electricity Last Winter, New Jersey and D.C. Bills Rose 25 Percent

November 17, 2026

Popular News

  • Discount Tire Delivers Low Prices and Price Matching Ahead of Black Friday

    0 shares
    Share 0 Tweet 0
  • Intercontinental Exchange Launches Data Center Risk Tool: NYSE Content Update

    0 shares
    Share 0 Tweet 0
  • Enterprise AI Executive Behind $2B+ in Value Joins Vibrant Capital’s CxO in Residence Program

    0 shares
    Share 0 Tweet 0
  • FairMarketValue Introduces Private-Company Financial Benchmarks Built on 1.24 Million Actual Financial Statements

    0 shares
    Share 0 Tweet 0
  • OpFix founder publishes 2 books on why founder-led businesses stall and what money really costs them

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler